In June of 2023 Fibrogen announced the results of the ZEPHYRUS-1 clinical trial of Pamrevlumab in IPF.  Pamrevlumab entered phase 3 with much anticipation.  Phase 2 work suggested that the molecule had a high chance of success.  Unfortunately, in the phase 3 study which included 356 subjects, Pamrevlumab was not effective at preserving lung function.  As a result, Fibrogen … [Read more...]